Some of the stocks that may grab investor focus today are:
CalAmp (NASDAQ: CAMP) issued a downbeat outlook for the fourth quarter. CalAmp shares dipped 8.35% to $25.26 in the after-hours trading session.
Anworth Mortgage Asset (NYSE: ANH) announced an additional 5 million share repurchase program. Anworth Mortgage shares rose 0.97% to $4.18 in after-hours trading.
Shares of Xyratex (NASDAQ: XRTX) jumped 27.27% yesterday after the company agreed to be acquired by Seagate Technology Plc (NASDAQ: STX) for around $374 million in cash. Xyratex shares fell 0.15% to $13.28 in the after-hours trading session, while Seagate shares rose 0.02% to $56.02 in after-hours trading.
Liberator Medical Holdings (NYSE: LBMH) reported a strong rise in its full-year earnings. Liberator Medical shares jumped 11.53% to $4.45 in the after-hours trading session.
Best European Companies To Invest In Right Now: Neuroderm Ltd (NDRM)
Neuroderm Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development of treatments for central nervous system (CNS) disorders. The Company develops liquid levodopa (LD), which is a treatment for Parkinson�� disease (PD). The Company designs product candidates that address needs in the field of Parkinson�� disease and cognition. The Company�� product pipelines includes ND0612L for moderate PD, ND0612H for severe PD, ND0680 for severe PD, ND0701 for severe PD and ND0801for Cognitive Disorders. The Company developed a liquid formulation of levodopa/carbidopa (LD/CD). The Company through its reformulation technology develops a line of LD/CD product candidates administered through a patch-pump or small belt pump that deliver a continuous, controlled dose of LD/CD to the blood stream. The Company�� LD/CD line of product candidates includes ND0612L, ND0612H and ND0680. The Company also develops ND0701, a formulation of continuous apomorphine therapy for the treatment of Parkinson�� disease.
ND0612L for moderate Parkinson�� disease
ND0612L is under development for the treatment of moderate Parkinson�� disease patients who can no longer effectively control their motor complications with oral levodopa. ND0612L is developed as a fixed dose liquid formulation of levodopa and carbidopa to be administered subcutaneously, over a day and night period. The product ND0612L has two versions under development: ND0612L belt pump version, which is subcutaneously administrated via a small belt-pump, and ND0612L Patch Pump Version, which is a second generation product that is subcutaneously administrated via a patch pump.
The Company has conducted two Phase I studies and a Phase IIa clinical study with N0612L. The clinical studies was a single-dose, 24-hour continuous-administration, randomized, double-blind, placebo-controlled study on eight subjects with moderate Parkinson�� disease. The study results demonstrated that subcutaneous deli! very of ND0612L was safe and tolerable, and achieved steady-state plasma levodopa concentrations of 700-900 nanogram/milliliter. Additionally, administration of ND0612L was shown to significantly reduce fluctuations in plasma levodopa concentrations.
The Company is conducting a Phase II randomized, placebo-controlled, double-blind study of ND0612L on approximately 30 Parkinson�� disease patients suffering from motor complications. The study�� primary endpoints are safety and tolerability, as well as the pharmacokinetic profile of levodopa plasma concentrations.
ND0612H for severe Parkinson�� disease
The Company is developing ND0612H for the treatment of severe-stage Parkinson�� disease patients for whom oral drugs are no longer effective. The ND0612H belt pump (CRONO Twin ND) is a drug pump that delivers levodopa/carbidopa (LD/CD) to treat severe Parkinson�� disease patients. ND0612H provides continuous subcutaneous delivery of an adjustable, high dose, LD/CD formulation to improve motor and non-motor complications in patients refractory to oral LD/CD. ND0612H�� is subcutaneously administrated utilizing a belt-pump allowing patients to receive continuous LD/CD therapy round the clock. The Company is conducting Phase II clinical trials on the product ND0612H for the treatment of severe-stage Parkinson�� disease.
ND0680 for severe Parkinson�� disease
ND0680 is indicated for the treatment of very severe Parkinson�� disease, which requires high doses of LD/CD which cannot be provided via oral delivery or using ND0612L and ND0612H. ND0680 is administered via a tube to the duodenum. ND0680 formulation contains a much higher concentration of LD/CD and is administered with the CRONO ND belt pump via the duodenum. The Company is conducting Phase I clinical trials for the development of ND0680
ND0701 for severe Parkinson�� disease
ND0701 is an apomorphine-based product candidate. ND0701 is desi! gned for ! the treatment of patients with severe Parkinson�� disease and do not respond well to LD/CD. ND0701 is administered via a CRONO ND belt pump or a patch pump (1st and 2nd generation, respectively). The Company is conducting Phase I clinical trials for the development of ND0701 indicated for the treatment of severe Parkinson�� disease.
ND0801 for Cognitive Disorders
ND0801 is under development for the treatment of cognition disorders associated with central nervous system diseases, such as Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder (ADD/ADHD), Alzheimer�� disease, Parkinson�� disease and schizophrenia. ND0801�� is covered by a reformulation and is designed to be a nicotine-based combination drug treatment. ND0801 is administered via a transdermal patch.
The Company is conducting tests on ND0801 for the treatment of ADD/ADHD in two centers in Israel in an open-label, Phase IIa, proof-of-concept dose escalation study on approximately 45 adult patients. The study is designed to demonstrate the safety, tolerability and optimal therapeutic doses of ND0801, and evaluate the cognitive improvement in subjects following treatment with escalating doses of ND0801. Interim results from 30 patients enrolled have demonstrated a dose dependent improvement in attention and cognition following seven days of ND0801 treatment with no observed serious side effects.
Advisors' Opinion:- [By Johanna Bennett]
NeuroDerm (NDRM) nearly doubled in value today, rising to $12.25 a share after more than 15 million shares changed hands, after the company reported positive results in a small trial for a treatment for Parkinson�� disease.
10 Best Medical Stocks To Watch For 2014: OncoSec Medical Inc (ONCS)
OncoSec Medical Incorporated, incorporated on February 8, 2008, is an emerging drug-medical device company. The Company focused on designing, developing and commercializing medical approaches for the treatment of solid cancers. In March 2011, the Company acquired from Inovio Pharmaceuticals, Inc. (Inovio) certain assets related to the use of drug-medical device combination products for the treatment of different cancers.
The Company�� acquired assets relate to certain non-deoxyribonucleic acid (DNA) vaccine technology and property relating to selective tumor ablation technologies, which it refers to as the OncoSec Medical System (OMS), a therapy which uses an electroporation device to facilitate delivery of chemotherapy agents, or nucleic acids encoding cytokines, into tumors and/or surrounding tissue for the treatment and diagnosis of various cancers. As of January 24, 2012, the Company had not generated any revenue from operations.
Advisors' Opinion:- [By James E. Brumley]
How does the old saying go? Beggars can't be choosers? Two weeks ago, yours truly penned some bullish comments regarding OncoSec Medical Inc. (OTCMKTS:ONCS). The long and short of it was, if ONCS could clear a technical ceiling around $0.36, then life would get much easier for the bulls.
- [By John Udovich]
Small cap biotech stocks AVEO Pharmaceuticals, Inc (NASDAQ: AVEO), OncoSec Medical Inc (OTCMKTS: ONCS) and MetaStat Inc (OTCBB: MTST) are focused on or are developing treatments or diagnostic technologies for metastatic cancers. In case you aren�� familiar with the term metastasis or metastatic, it�� the�spread of cancer from its primary site to other places in the body as cancer cells break away from a primary tumor, penetrate into lymphatic and blood vessels, circulate through the bloodstream and then grow in a new focus (metastasize) in normal tissues elsewhere in the body. In other words, it�� a dangerous form of cancer, but there are some small cap biotech stocks targeting it for diagnostics or treatment:
10 Best Medical Stocks To Watch For 2014: BIND Therapeutics Inc (BIND)
BIND Therapeutics, Inc., incorporated on May 19, 2006, is a clinical-stage nanomedicine platform company developing Accurins, its targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Its drug candidate, BIND-014, is in Phase II clinical trials for non-small cell lung cancer, or NSCLC, and metastatic castrate-resistant prostate cancer (mCRPC).
Accurins represent the evolution of targeted therapies and nanomedicine. Accurins are polymeric nanoparticles that incorporate a therapeutic payload and are designed to have prolonged circulation within the bloodstream, enable targeting of the diseased tissue or cells, and provide for the controlled and timely release of the therapeutic payload. The four components include Targeting ligands, Stealth and protective layer, Controlled-release polymer matrix and Therapeutic payload. The Company focuses to use its medicinal nanoengineering platform to develop Accurins in several therapeutic areas, with an initial focus on the treatment of various types of cancer. In addition, the Company entered into collaboration agreements with several biopharmaceutical companies to develop and commercialize Accurins that are based on its collaborators��therapeutic payloads. The Company�� programs include BIND-014, solid tumor accurin and hematologic cancer accurin.
Advisors' Opinion:- [By John Udovich]
If you have not been watching the biotech sector lately, you should start paying attention as the sector along with small cap biotech stocks like Cell Therapeutics Inc (NASDAQ: CTIC), BIND Therapeutics Inc (NASDAQ: BIND) and TNI BioTech (OTCMKTS: TNIB) continue to produce a steady stream of good news for investors thanks to positive industry trends. Moreover, Ophthotech Corp (NASDAQ: OPHT), Foundation Medicine Inc (NASDAQ: FMI), Evoke Pharma and Fate Therapeutics Inc (NASDAQ: FATE) are this week's biotech IPOs that will no doubt be watched closely by Wall Street and industry observers in general. With that in mind, consider the following biotech news or recent articles about the industry and the small cap players in it:
- [By Garrett Cook]
BIND Therapeutics (NASDAQ: BIND) was down, falling 10.56 percent to $11.52 after the company reported the closing of collaboration deal with Amgen (NASDAQ: AMGN).
- [By John Udovich]
Yesterday, small cap biotech Acceleron Pharma Inc (NASDAQ: XLRN) rose 9.76%�plus shares are up 183.6% for retail investors since its September IPO, meaning its worth taking a closer look at the stock along with the performance of other biotech IPOs like BIND Therapeutics Inc (NASDAQ: BIND), Ophthotech Corp (NASDAQ: OPHT) and Foundation Medicine Inc (NASDAQ: FMI) which also debuted at the same time.
10 Best Medical Stocks To Watch For 2014: Spectral Diagnostics Inc (DIAGF)
Spectral Diagnostics Inc. (Spectral), incorporated on July 29, 1991, focuses on the development and commercialization, in North America, treatment for severe sepsis and septic shock. The Company also manufactures and sells certain reagents. Its products include Rapid Diagnostics for Sepsis, Endotoxin Activity Assay (EAA) and Toraymyxin. As of December 31, 2011, Spectral�� EAA endotoxin measurement was the only the United Sates Food and Drug Administration (FDA) cleared diagnostic on the market. Spectral Diagnostics (US) Inc. and Spectral Diagnostics (New Brunswick) Inc. are its subsidiaries.
The Company has developed a rapid diagnostic test for detection of components of gram negative bacterial cell wall (endotoxin). The EAA instrument is manufactured under contract for use in the hospital setting. The Toraymyxin hemoperfusion device removes endotoxin from the bloodstream and is manufactured by Toray Industries Inc. of Japan. The product is sold in Japan and Europe and has been used over 80,000 patients worldwide. As of December 31, 2011, Spectral was conducting clinical trials for the purpose of seeking regulatory approval in the United States. Spectral develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies. Royalty revenues are earned from these license arrangements based on a percentage of end user sales of Troponin I.
The Company competes with Eli Lilly, Agennix AG, AstraZeneca, Eisai, Gambro, InflammaGen Therapeutics, Fresenius and CytoSorbents.
Advisors' Opinion:- [By maarnio]
Spectral Diagnostics (DIAGF) develops and commercializes theranostic treatment for severe sepsis in North America.
Shares outstanding (March 31, 2014)
10 Best Medical Stocks To Watch For 2014: HeartWare International Inc (HTWR)
Heartware International, Inc. (HeartWare), incorporated on June 25, 2010, develops and manufactures small implantable heart pumps, or ventricular assist devices, for the treatment of advanced heart failure. The HeartWare Ventricular Assist System (the HeartWare System), which includes a ventricular assist device (VAD), or blood pump, patient accessories and surgical tools, is designed to provide circulatory support for patients in the advanced stage of heart failure. The core of the HeartWare System is a continuous flow blood pump, the HVAD Pump, which is a full-output device capable of pumping up to 10 liters of blood per minute. The HeartWare System is designed to be implanted adjacent to the heart, avoiding the abdominal surgery generally required to implant similar devices. In August 2012, it acquired World Heart Corporation. As of December 31, 2012, the HeartWare System has been implanted outside of the United States at approximately 168 health care sites in 28 countries. In December 2013, HeartWare International Inc acquired CircuLite, Inc.
Proprietary Pump Technology
The HeartWare System is full-output centrifugal pump designed to be implanted in the chest, directly adjacent to the heart. At the core of the Company�� technology platform is its hybrid system for suspending the impeller, which is the only moving part within the pump. The impeller is suspended within the pump housing by the opposing forces of passive magnets and hydrodynamic thrust generated by the pump impeller, which circulates a cushion of
blood. Once power is applied to the device and the impeller begins to rotate, there are no points of mechanical contact within the pump, thus providing a completely wearless pumping system.
The HeartWare System
The HeartWare System consists of the HVAD Pump, a small, permanently implantable VAD, patient accessories and surgical tools. The HVAD Pump is capable of generating up to 10 liters of blood flow per minute. With a displaced v! olume of only 50 cubic centimeters and a mass of 140 grams, the HVAD Pump is the only full-output pump implantable in the pericardial space, directly adjacent to the heart. It is also the only pump designed to be implanted above the diaphragm in all eligible patients.
The HeartWare MVAD
The miniaturized ventricular assist device (MVAD) is a miniaturized blood pump intended for chronic heart failure patients. The device is a full-output axial flow pump with a fully suspended rotor and a displacement volume approximately one-third that of the HVAD Pump.
The Company competes with Thoratec Corporation, Jarvik Heart, MicroMed Technology, Inc, Berlin Heart AG, Terumo Heart, Inc., Sunshine Heart, Inc and CircuLite, Inc., Evaheart Medical USA, Inc.
Advisors' Opinion:- [By Maria Armental var popups = dojo.query(".socialByline .popC"); popups.forEach]
HeartWare International Inc.(HTWR) said it received a warning letter from the U.S. Food and Drug Administration, citing concerns about procedures for validating device design and other issues.
- [By Todd Campbell]
Competing for heart pump market share
Abiomed's products provide circulatory support for up to six hours and are designed for use in cardiac cath labs or during heart surgery, but competitors Thoratec (NASDAQ: THOR ) and Heartware (NASDAQ: HTWR ) target the intermediate- and long-term-use market instead. - [By Lauren Pollock]
Medical device company HeartWare International Inc.(HTWR) issued a revenue forecast that fell short of market expectations.
Intrepid Potash Inc.(IPI), the largest potash producer in the U.S., plans to cut its workforce by 7% and cut executive compensation as part of a plan to trim costs in reaction to weaker prices for the fertilizer ingredient.
10 Best Medical Stocks To Watch For 2014: Bio-Path Holdings Inc (BPTH)
Bio-Path Holdings Inc is a development stage company. The Company, through its wholly owned subsidiary, Bio-Path, Inc. is engaged in the business of developing cancer therapeutics. As of December 31, 2011, the Company had licenses from The University of Texas M. D. Anderson Cancer Center (MD Anderson) for three lead products and nucleic acid delivery technology, including tumor targeting technology. The licenses provide drug delivery platform technology with composition of matter intellectual property for antisense that enables systemic delivery of antisense, formulation intellectual property for systemic delivery of small interfering Ribonucleic acid (RNA) (siRNA) and small molecules for treatment of cancer. The Company issued a press release announcing that the United States Food and Drug Administration (FDA) had allowed an IND (investigational new drug) for its lead cancer drug candidate liposomal BP-100-1.01 (or Liposomal Grb-2 or L-Grb-2) to proceed into clinical trials.
In February, 2012, the Company completed requirements for treating patients in the second cohort. The dose being used for treatment in the third cohort is double the dose that was used to treat patients in the second cohort. At the end of February, 2012, enrollment continued in the third cohort of the clinical trial and patients are being treated.
BP-100-1.01
BP-100-1.01 is the Company's lead lipid delivery antisense drug candidate, which is being clinically tested in patients having acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), myelodysplastic syndrome (MDS) and acute lymphoblastic leukemia (ALL). Receipt of an IND allowed the Company to commence its Phase I clinical trial to study L-Grb-2 in human patients. Phase I clinical trial is a dose-escalating study to determine the safety and tolerance of escalating doses of L-Grb-2. The clinical trial is being conducted at The University of Texas MD Anderson Cancer Center. As of December 31, 2011, the trial is in the middle of ! testing the third dose in patients.
BP-100-2.01
BP-100-1.02 is Liposomal Bcl-2 (also L-Bcl-2), another liposomal antisense drug candidate that was licensed from MD Anderson. This drug has pre-clinical testing data package. The target protein for this drug candidate, Bcl-2, is involved in regulating programmed cell death. In cancer, the Bcl-2 protein can over-express, which can lead to a situation, in which the Bcl-2 protein blocks the cell�� normal death signals, making the cancer cell resistant to chemotherapy. Types of cancer potentially treatable with L-Bcl-2 include lymphoma, prostate cancer, small cell lung cancer, breast cancer, melanoma, chronic lymphoid leukemia (CLL) and several others.
Advisors' Opinion:- [By Lisa Levin]
Bio-Path Holdings (NASDAQ: BPTH) shares declined 5.66% to touch a new 52-week low of $2.50. Bio-Path shares have jumped 349.15% over the past 52 weeks, while the S&P 500 index has gained 19.24% in the same period.
10 Best Medical Stocks To Watch For 2014: Landauer Inc (LDR)
Landauer, Inc. (Landauer) is a provider of technical and analytical services to determine occupational and environmental radiation exposure. The Company is domestic provider of outsourced medical physics services. The Company operates in two segments: Radiation Monitoring and Medical Physics. The Company has provided radiation dosimetry services to hospitals, medical and dental offices, universities, national laboratories, nuclear facilities and other industries. Landauer's services include the manufacture of radiation detection monitors, the distribution and collection of the monitors to and from customers, and the analysis and reporting of exposure findings. In addition to providing analytical services, the Company leases or sells dosimetry detectors and reading equipment to customers. Medical physics services are provided through the Company's Global Physics Solutions, Inc. (GPS) subsidiary. In November 2011, it acquired IZI Medical Products, LLC.
In November 2009, Landauer completed the acquisition of GPS. GPS is a nationwide service provider of clinical physics support, equipment commissioning and accreditation support and imaging equipment testing. In June 2010, Landauer, through its GPS subsidiary, completed the acquisition of Upstate Medical Physics (UMP), a provider of imaging physics services in New York. In November 2009, Landauer completed the acquisition of Gammadata Matteknik AB (GDM), a Swedish provider of radon measurement services. GDM provides measurement services throughout the Scandinavian region and Europe. In October 2009, Landauer completed the acquisition of dosimetry service in Sweden, called Landauer Persondosimetri AB (PDM).
The Radiation Monitoring revenues are realized from radiation monitoring services and other services incidental to radiation dose measurement. The Company enters into agreements with customers to provide them with radiation monitoring services, for a 12 month period. As part of its services, the Company provides to its custome! rs radiation detection badges, which are produced and owned by the Company. The badges are worn for a period selected by the customers (wear period), which is usually one, two, or three months in duration. At the end of the wear period, the badges are returned to the Company for analysis. The Company analyzes the badges that have been worn and provides its customers with a report indicating their radiation exposures. The Company recycles certain badge components for reuse, while also producing replacement badges on a continual basis.
The Company offers its service for measuring the dosages of x-ray, gamma radiation and other penetrating ionizing radiations, to which the wearer has been exposed, through badges, which contain optically stimulated luminescent (OSL) material, which are worn by customer personnel. This technology is marketed under the trade names Luxel+ and InLight. A component of the Company's dosimetry system is OSL crystal material. The Company's base OSL material is manufactured utilizing a process to create aluminum oxide crystals in a structure that is able to retain charged electrons following the crystal's exposure to radiation.
Landauer's InLight dosimetry system provides in-house and commercial laboratories with the ability to provide in-house radiation monitoring services using OSL technology. InLight services involve a customer acquiring or leasing dosimetry devices, as well as analytical reading equipment from the Company. The InLight system allows customers the flexibility to tailor their dosimetry needs. Landauer's operations include services for the measurement and monitoring of radon gas. The Company offers a service, which provides radon monitoring and, when necessary, remediation to purchasers of personal residences. Testing requires the customer to deploy a radon detector and return the detector to the Company's laboratories for dose determination and reporting. The Company assists with remediation services on properties where radon measurements ! exceed a ! specified threshold.
The Company competes with Mirion Technologies.
Advisors' Opinion:- [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Landauer (NYSE: LDR ) , whose recent revenue and earnings are plotted below.
No comments:
Post a Comment